-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| Research on domestically produced original innovative drugs led by Chinese scholars brings new results |
Science and Technology Daily reporter Ma Aiping
In the early morning of June 7th, Beijing time, Professor Xu Ruihua, Director and Dean of Sun Yat-sen University Cancer Center, was invited to give a report at the annual meeting of the American Society of Clinical Oncology (ASCO), a global oncology event, introducing the JUPITER-02 study (abstract number) : LBA2) Achievement.
This is the first Chinese innovative drug research selected into the plenary session in the official records of the ASCO annual meeting
.
"Blockbuster Research Abstract" (LBA) is also known as "Delayed Publication Abstract".
This year, only 5 LBAs emerged from nearly 10,000 submissions to enter the ASCO Plenary session, which is considered to be the most important this year.
, It is expected to change the clinical diagnosis and treatment practice and have sensational research results.
Therefore, the ASCO organizers will keep confidential in advance, and will not release the complete data until the day of the general meeting, and hold a press conference to give a detailed introduction
.
The subject of Xu Ruihua's report is "JUPITER-02: A randomized, double-blind, phase III clinical study comparing teriprizumab or placebo combined with gemcitabine and cisplatin in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma", He is also the chief scientist of this research
.
"The results of the JUPITER-02 study are encouraging and are expected to rewrite the global first-line treatment standard for recurrent/metastatic nasopharyngeal carcinoma
"Compared with some other types of cancer, the treatment of advanced nasopharyngeal carcinoma has fallen behind, but the results of the JUPITER-02 study will change our approach to nasopharyngeal carcinoma,
" said Dr.
Julie R.
Since 2016, Xu Ruihua's team has been cooperating with local pharmaceutical company Junshi Bio
.
From the small sample size exploratory study of phase Ib/II, the second-line and subsequent-line treatment research of phase II immunization, to the world’s largest international multi-center first-line study of “immunotherapy + chemotherapy”, the JUPITER-02 study.
The JUPITER-02 study is the world's first multicenter, randomized, double-blind, placebo-controlled phase III clinical study of recurrent/metastatic nasopharyngeal carcinoma
.
A total of 35 centers including China, Taiwan, and Singapore participated.
Taiwan Taiwan
"It is a great honor and encouragement for us to be selected for the important research of the plenary meeting of the ASCO annual meeting.
It not only shows that the academic level of China's tumor treatment field is continuously improving, but also shows that the research and development of Chinese drugs is no longer purely At the stage of imitation, it has achieved unique innovation
.
” said Yao Sheng, Senior Vice President of Junshi Biology
Mai Haiqiang, a core member of the JUPITER-02 research team and a professor at Sun Yat-sen University Cancer Center, said: “The research of domestically produced new drugs led by Chinese scholars has reached the top of the world’s top tumor conferences, representing more and more'Chinese solutions' to gain the height of the international academic community.
Definitely
.
"
